Literature DB >> 1351039

Transthyretin Pro55, a variant associated with early-onset, aggressive, diffuse amyloidosis with cardiac and neurologic involvement.

D R Jacobson1, D E McFarlin, I Kane, J N Buxbaum.   

Abstract

Mutations in the protein transthyretin cause amyloidosis involving the heart, peripheral nerves, and other organs. A family from West Virginia developed an unusually aggressive form of widespread transthyretin amyloidosis. Single-strand conformation polymorphism analysis revealed a variant in the transthyretin gene, which was found on sequencing to be a T----C transversion at position 2 of codon 55, corresponding to a Leu----Pro substitution. The variant sequence was confirmed by restriction analysis and polymerase chain reaction (PCR)-primer introduced restriction analysis.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1351039     DOI: 10.1007/bf00220559

Source DB:  PubMed          Journal:  Hum Genet        ISSN: 0340-6717            Impact factor:   4.132


  9 in total

1.  Primary familial amyloidosis.

Authors:  H E KAUFMAN
Journal:  AMA Arch Ophthalmol       Date:  1958-12

2.  Rapid and sensitive detection of point mutations and DNA polymorphisms using the polymerase chain reaction.

Authors:  M Orita; Y Suzuki; T Sekiya; K Hayashi
Journal:  Genomics       Date:  1989-11       Impact factor: 5.736

3.  Rapid, nonradioactive screening for activating ras oncogene mutations using PCR-primer introduced restriction analysis (PCR-PIRA)

Authors:  D R Jacobson; T Moskovits
Journal:  PCR Methods Appl       Date:  1991-11

Review 4.  Genetic aspects of amyloidosis.

Authors:  D R Jacobson; J N Buxbaum
Journal:  Adv Hum Genet       Date:  1991

5.  A specific test for transthyretin 122 (Val----Ile), based on PCR-primer-introduced restriction analysis (PCR-PIRA): confirmation of the gene frequency in blacks.

Authors:  D R Jacobson
Journal:  Am J Hum Genet       Date:  1992-01       Impact factor: 11.025

6.  From molecular variant to disease: initial steps in evaluating the association of transthyretin M119 with disease.

Authors:  S Ii; J L Sobell; S S Sommer
Journal:  Am J Hum Genet       Date:  1992-01       Impact factor: 11.025

7.  Primary familial amyloidosis.

Authors:  V G Wong; D E McFarlin
Journal:  Arch Ophthalmol       Date:  1967-08

8.  Amyloid in hereditary amyloid polyneuropathy is related to prealbumin.

Authors:  M C Dalakas; W K Engel
Journal:  Arch Neurol       Date:  1981-07

9.  Measles virus-specific T4+ human cytotoxic T cell clones are restricted by class II HLA antigens.

Authors:  S Jacobson; J R Richert; W E Biddison; A Satinsky; R J Hartzman; H F McFarland
Journal:  J Immunol       Date:  1984-08       Impact factor: 5.422

  9 in total
  33 in total

1.  Sulfated glycosaminoglycans accelerate transthyretin amyloidogenesis by quaternary structural conversion.

Authors:  Steve Bourgault; James P Solomon; Natàlia Reixach; Jeffery W Kelly
Journal:  Biochemistry       Date:  2011-01-24       Impact factor: 3.162

2.  The molecular interaction of 4'-iodo-4'-deoxydoxorubicin with Leu-55Pro transthyretin 'amyloid-like' oligomer leading to disaggregation.

Authors:  M P Sebastião; G Merlini; M J Saraiva; A M Damas
Journal:  Biochem J       Date:  2000-10-01       Impact factor: 3.857

3.  Evidence for early cytotoxic aggregates in transgenic mice for human transthyretin Leu55Pro.

Authors:  Mónica Mendes Sousa; Rui Fernandes; Joana Almeida Palha; Ana Taboada; Paulo Vieira; Maria João Saraiva
Journal:  Am J Pathol       Date:  2002-11       Impact factor: 4.307

4.  Unusual duplication mutation in a surface loop of human transthyretin leads to an aggressive drug-resistant amyloid disease.

Authors:  Elena S Klimtchuk; Tatiana Prokaeva; Nicholas M Frame; Hassan A Abdullahi; Brian Spencer; Surendra Dasari; Haili Cui; John L Berk; Paul J Kurtin; Lawreen H Connors; Olga Gursky
Journal:  Proc Natl Acad Sci U S A       Date:  2018-06-25       Impact factor: 11.205

5.  Enhanced expression of human cDNA by phosphoglycerate kinase promoter-puromycin cassette in the mouse transthyretin locus.

Authors:  Zhenghua Li; Gang Zhao; Jingling Shen; Kimi Araki; Kyoko Haruna; Seiya Inoue; Jun Wang; Ken-ichi Yamamura
Journal:  Transgenic Res       Date:  2010-04-06       Impact factor: 2.788

Review 6.  The transthyretin amyloidoses: from delineating the molecular mechanism of aggregation linked to pathology to a regulatory-agency-approved drug.

Authors:  Steven M Johnson; Stephen Connelly; Colleen Fearns; Evan T Powers; Jeffery W Kelly
Journal:  J Mol Biol       Date:  2012-01-05       Impact factor: 5.469

7.  Transthyretin Pro 36 associated with familial amyloidotic polyneuropathy in an Ashkenazic Jewish kindred.

Authors:  D R Jacobson; C J Rosenthal; J N Buxbaum
Journal:  Hum Genet       Date:  1992 Sep-Oct       Impact factor: 4.132

8.  Switch region for pathogenic structural change in conformational disease and its prediction.

Authors:  Xin Liu; Ya-Pu Zhao
Journal:  PLoS One       Date:  2010-01-11       Impact factor: 3.240

9.  Potentially amyloidogenic conformational intermediates populate the unfolding landscape of transthyretin: insights from molecular dynamics simulations.

Authors:  J Rui Rodrigues; Carlos J V Simões; Cândida G Silva; Rui M M Brito
Journal:  Protein Sci       Date:  2010-02       Impact factor: 6.725

10.  Tissue distribution, biochemical properties, and transmission of mouse type A AApoAII amyloid fibrils.

Authors:  Tatsumi Korenaga; Xiaoying Fu; Yanming Xing; Takatoshi Matsusita; Kazunao Kuramoto; Seigo Syumiya; Kazuhiro Hasegawa; Hironobu Naiki; Masaki Ueno; Tokuhiro Ishihara; Masanori Hosokawa; Masayuki Mori; Keiichi Higuchi
Journal:  Am J Pathol       Date:  2004-05       Impact factor: 4.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.